WhatPeptide

CagriSema

CagriSema is a fixed-dose co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) that demonstrated superior weight loss to either component alone in Phase 3 REDEFINE trials. The combination targets complementary appetite-regulating pathways simultaneously.

Strong evidence Investigational Amylin/GLP-1 Combination

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Currently in clinical trials — not yet approved for any indication.
Combination of cagrilintide (amylin analog) + semaglutide (GLP-1 agonist). Proprietary Novo Nordisk product.

Half-life

Approximately 7 days (semaglutide component dominant)

Dosage range

2.4 mg semaglutide / 2.4 mg cagrilintide once weekly (phase 3)

Administration

Subcutaneous injection

Research level

Strong

How CagriSema works

By co-activating GLP-1 receptors via semaglutide and amylin receptors via cagrilintide, CagriSema achieves additive reductions in food intake, gastric emptying, and body weight beyond what either monotherapy achieves alone. Phase 3 REDEFINE-1 data reported approximately 22-25% body weight reduction at the highest dose over 68 weeks. The dual-pathway approach may also improve glycemic control and cardiometabolic risk factors.

Also known as: Cagrilintide + Semaglutide, AM833 + OG217SC

Clinical trial efficacy

REDEFINE-1 Phase 3: -22.7% (trial-product estimand) / -20.4% (treatment-policy estimand) body weight at 68 weeks, superior to semaglutide monotherapy.

Research relevance

Fat Loss
Strong research relevance 95

Side effects & safety

Nausea Vomiting Diarrhea Constipation Injection site reactions Pancreatitis (rare but serious) Thyroid C-cell tumors (class-based preclinical signal — rodent data, human relevance uncertain) Potential lean mass loss alongside fat loss

Contraindications

History of medullary thyroid carcinoma
MEN2
Pregnancy
Severe gastrointestinal disease

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is CagriSema? +
CagriSema is a fixed-dose co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) that demonstrated superior weight loss to either component alone in Phase 3 REDEFINE trials. The combination targets complementary appetite-regulating pathways simultaneously. Its mechanism of action is supported by robust clinical evidence.
What is CagriSema researched for? +
CagriSema has the strongest research relevance for Fat Loss. Evidence is supported by robust clinical evidence.
What are the side effects of CagriSema? +
Reported side effects include Nausea, Vomiting, Diarrhea, Constipation, Injection site reactions, Pancreatitis (rare but serious), Thyroid C-cell tumors (class-based preclinical signal — rodent data, human relevance uncertain), Potential lean mass loss alongside fat loss. Key contraindications: History of medullary thyroid carcinoma; MEN2; Pregnancy; Severe gastrointestinal disease.
Is CagriSema FDA approved? +
CagriSema is currently in clinical trials and is not yet approved by the FDA.
How is CagriSema administered? +
CagriSema is typically administered via subcutaneous route. Researched dosage range: 2.4 mg semaglutide / 2.4 mg cagrilintide once weekly (phase 3). Half-life: Approximately 7 days (semaglutide component dominant).

Explore similar peptides

Retatrutide

Preliminary evidence

GLP-1/GIP/Glucagon Agonist

An investigational triple agonist (GLP-1/GIP/glucagon) with large early-stage weight-loss signals in phase 2 studies.

Semaglutide

Strong evidence

GLP-1 Agonist

A long-acting GLP-1 receptor agonist with robust randomized evidence for glycemic control and body-weight reduction.

Tirzepatide

Strong evidence

GIP/GLP-1 Agonist

A dual GIP/GLP-1 receptor agonist with strong evidence for substantial weight loss and glycemic improvement in phase 3 trials.

Mazdutide

Moderate evidence

GLP-1/Glucagon Agonist

Mazdutide is a once-weekly dual GLP-1 receptor and glucagon receptor co-agonist in late-stage clinical development for obesity and type 2 diabetes, showing significant weight loss in Phase 3 trials predominantly conducted in the Asia-Pacific region. The glucagon component adds hepatic fat mobilization and energy expenditure to GLP-1-mediated appetite suppression.